We have changed our name from Solid Tumor Translational Research to Seattle Translational Tumor Research (STTR) to better reflect our widening scope. We now have experts across more than fifteen blood, lymphatic and solid tumors – anogenital cancers (anal, cervical, penile, vagninal, and vulvar cancers), bladder, brain, breast, colorectal, head & neck, leukemia, lymphoma, lung, myelodysplastic/myeloproliferative disease, myeloma, ovary, pancreas, prostate and sarcoma.
STTR is transformative movement creating a strong sense of community among Seattle’s cancer investigators. Located in Seattle, the STTR group is comprised of investigators from four leading Northwest institutions - Fred Hutchinson Cancer Research Center, UW Medicine, Seattle Cancer Care Alliance and Seattle Children’s Hospital.
Our vision is an environment tailored to researchers and clinicians which allows them to accelerate scientific discovery and translate it into cures for patients, both regionally and globally. With the support from our philanthropic partners, we are poised to make major research advances that will significantly improve patient quality of life and survival.
STTR's multidisciplinary, multi-institutional team includes experts in mathematical modeling, computer simulation, visualization, bioengineering, big data mining, cancer biology, precision oncology, population science and the best clinicians in the field.
We are using state-of-the-art technology and scientific innovation to speed translational research and more rapidly turn laboratory findings, populations studies and clinical insights into clinical practice and population-level recommendations. The goals of the program are to enhance the understanding of cancer biology and therapeutic responses and to identify personalized treatments that improve patient outcomes.
Initially, we established programs for tumors of the brain, breast, colon, head and neck, lung, ovary, pancreas and prostate. After the first year, we added bladder cancer and sarcoma. In 2016, we added anogenital cancers, leukemia, lymphoma, myelodysplastic/myeloproliferative disorder and myeloma. Using genomics, bioinformatics, mathematical modeling and other techniques, scientists and clinicians compare patient information with laboratory findings to tailor treatment options.
STTR fosters and promotes intellectual participation and collaboration with lectures, retreats, working groups, protocol development, biospecimen collection and utilization, joint publications and grants.
We believe there are many promising cancer therapies on the horizon. Combining our expertise will enable the design and delivery of the new therapies more efficiently and quickly to patients.
We would like to hear from you or share our newsletter with you. Send us your questions or comments or subscribe to our newsletter.